BCR-ABL1 p230(μbcr) Detection Kit
£1,274.00
The geneMAP™ BCR-ABL1 P230(µbcr) Detection Kit for Leukemia are intended for the quantitative detection of micro BCR-ABL1(p230) e19a2, fusion transcripts in bone marrow or peripheral blood samples. The results obtained are intended to be used as an aid to monitor efficacy of treatment in patients undergoing therapy, and for minimal residual disease (MRD) follow-up to monitor disease relapse.
- Superior Analytical Sensitivity: Achieves a log4 reduction, ensuring high sensitivity in detecting low levels of the BCR-ABL1 p230 fusion transcript.
- One Step RT-qPCR Technology: Simplifies the detection process, making it both fast and user-friendly.
- Multiplex PCR: Enables accurate relative quantitation by comparing fusion transcripts to ABL1 gene expression.
- Instrument Compatibility: Designed for use with FAM and VIC/HEX dual-color real-time PCR instruments, broadening its utility in various laboratory settings.
- CE-IVD Certification: Meets European standards for in vitro diagnostic medical devices, affirming the kit’s reliability and quality.
Leukemia Diagnosis and Monitoring: Specifically designed for the detection of the BCR-ABL1 p230 fusion gene in patients suspected of having chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia (ALL), aiding in diagnosis and treatment monitoring.
- Technology: Utilizes one-step RT-qPCR with multiplex PCR for the detection and relative quantitation of the BCR-ABL1 p230 fusion transcript.
- Sensitivity: Superior analytical sensitivity (log4 reduction) for detecting low levels of the target gene.
- Compatibility: Compatible with FAM and VIC/HEX dual-color real-time PCR instruments.
- Certification: CE-IVD marked, indicating compliance with EU regulations for in vitro diagnostic use.
Why Choose Clent
We strive to enable our customers to focus on the results of their work, rather than the tools they use. Need to speak with a member of our team? Get in touch today.
